Medtronic (MDT) Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Medtronic, Inc. (MDT) PT Raised to $155 at Jefferies
August 25, 2021 7:30 AM EDTJefferies analyst Raj Denhoy raised the price target on Medtronic, Inc. (NYSE: MDT) to $155.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "MDT posted a ~$120mn/$0.10 beat on out-performance in MedSurg on elective procedure recovery, share gains in Cardio/Micra,... More
Medtronic, Inc. (MDT) PT Raised to $145 at Stifel
August 25, 2021 6:33 AM EDTStifel analyst Rick Wise raised the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $140.00) while maintaining a Buy rating.
The analyst commented, "Despite some signs of new COVID-related slowdowns in late-July, Medtronic did start the F2022 year with a better-than-expected overall performance. Nicely-exceeding Stifel/Consensus estimates (Sales: $7.866B/$7.871B; EPS: $1.32), Medtronic reported F1Q sales... More
